NASDAQ:ONCO Onconetix (ONCO) Stock Price, News & Analysis $0.65 -0.01 (-1.83%) As of 10:10 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Onconetix Stock (NASDAQ:ONCO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Onconetix alerts:Sign Up Key Stats Today's Range$0.63▼$0.6650-Day Range$0.61▼$1.1152-Week Range$0.59▼$209.50Volume29,189 shsAverage Volume1.23 million shsMarket Capitalization$2.84 millionP/E Ratio0.00Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Onconetix, Inc. is a biotechnology company focused on developing and commercializing products for men’s health and oncology. The company’s activities center on therapies and diagnostic technologies intended to address conditions affecting the prostate and related areas of healthcare. Onconetix’s lead commercial product is ENTADFI, an oral combination of tadalafil and finasteride approved by the U.S. Food and Drug Administration for the treatment of the signs and symptoms of benign prostatic hyperplasia, or BPH, in men with an enlarged prostate. Tadalafil may help improve urinary symptoms, while finasteride is intended to reduce prostate size over time. The company was formerly known as Blue Water Vaccines and adopted the Onconetix name as its business strategy shifted toward men’s health and oncology. Its operations and commercial focus are primarily directed toward the United States. Information about additional products, geographic expansion and current leadership may change as the company develops its pipeline and commercialization strategy.AI Generated. May Contain Errors. Read More Onconetix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreONCO MarketRank™: Onconetix scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingOnconetix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageOnconetix has only been the subject of 1 research reports in the past 90 days.Read more about Onconetix's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconetix is 0.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconetix is 0.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.94.Price to Book Value per Share RatioOnconetix has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Onconetix's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.10% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.13, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently decreased by 19.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnconetix does not currently pay a dividend.Dividend GrowthOnconetix does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Onconetix this week, compared to 2 articles on an average week.Search Interest6 people have searched for ONCO on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows1 people have added Onconetix to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Onconetix insiders have not sold or bought any company stock.Percentage Held by Insiders0.27% of the stock of Onconetix is held by insiders.Percentage Held by Institutions23.89% of the stock of Onconetix is held by institutions.Read more about Onconetix's insider trading history. Receive ONCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONCO Stock News HeadlinesFinancial Analysis: Editas Medicine (NASDAQ:EDIT) & Onconetix (NASDAQ:ONCO)October 7 at 4:59 AM | americanbankingnews.comOnconetix (NASDAQ:ONCO) vs. Lucid Diagnostics (NASDAQ:LUCD) Head to Head ContrastOctober 5 at 5:44 AM | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 7 at 1:00 AM | InvestorPlace (Ad)SRX Global Liquidates 2 Portfolio Investments, Adds Onconetix Ahead Of Realbotix DealSeptember 26, 2026 | rttnews.comSRX Global Inc: SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)September 25, 2026 | finanznachrichten.deSRX Global Makes Investment in OnconetixSeptember 24, 2026 | finance.yahoo.comSRX Global Inc. acquired an unknown minority stake in Onconetix, Inc..September 24, 2026 | marketscreener.comMOnconetix, Inc.: CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending AcquisitionSeptember 15, 2026 | finanznachrichten.deSee More Headlines ONCO Stock Analysis - Frequently Asked Questions How have ONCO shares performed this year? Onconetix's stock was trading at $78.00 at the start of the year. Since then, ONCO shares have decreased by 99.2% and is now trading at $0.6560. How were Onconetix's earnings last quarter? Onconetix, Inc. (NASDAQ:ONCO) released its earnings results on Thursday, August, 13th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($4,505.00) by $4,503.72. The business earned $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Onconetix had a negative net margin of 1,575.89% and a negative trailing twelve-month return on equity of 91.95%. When did Onconetix's stock split? Onconetix's stock reverse split on Friday, May 22nd 2026.The 1-10 reverse split was announced on Tuesday, May 19th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 21st 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Onconetix IPO? Onconetix (ONCO) raised $20 million in an initial public offering on Thursday, February 17th 2022. The company issued 2,222,222 shares at $8.00-$10.00 per share. How do I buy shares of Onconetix? Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Onconetix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include Qualcomm (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI). Company Calendar Last Earnings8/13/2026Today10/07/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ONCO's financial health is in the Red zone, according to TradeSmith. ONCO has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ONCO Previous SymbolNASDAQ:ONCO CIK1782107 Webwww.onconetix.com Phone513-620-4101FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)$248.12 Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.03 million Net Margins-1,575.89% Pretax Margin-1,575.89% Return on Equity-91.95% Return on Assets-53.76% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio2.14 Sales & Book Value Annual Sales$810 thousand Price / Sales3.55 Cash FlowN/A Price / Cash FlowN/A Book Value$505.29 per share Price / Book0.00Miscellaneous Outstanding Shares4,380,000Free Float4,368,000Market Cap$2.87 million OptionableN/A Beta2.61 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ONCO) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONCO Stock Alerts